izpis_h1_title_alt

Potent DNA gyrase inhibitors bind asymmetrically to their target using symmetrical bifurcated halogen bonds
ID Kolarič, Anja (Author), ID Germe, Thomas (Author), ID Hrast, Martina (Author), ID Stevenson, Clare E. M. (Author), ID Lawson, David M. (Author), ID Burton, Nicolas P. (Author), ID Vörös, Judit (Author), ID Maxwell, Anthony (Author), ID Minovski, Nikola (Author), ID Anderluh, Marko (Author)

.pdfPDF - Presentation file, Download (2,00 MB)
MD5: 00DFF7317DB718CDA1A6E440A9F4B62B
URLURL - Source URL, Visit https://www.nature.com/articles/s41467-020-20405-8 This link opens in a new window

Abstract
Novel bacterial type II topoisomerase inhibitors (NBTIs) stabilize single-strand DNA cleavage breaks by DNA gyrase but their exact mechanism of action has remained hypothetical until now. We have designed a small library of NBTIs with an improved DNA gyrase-binding moiety resulting in low nanomolar inhibition and very potent antibacterial activity. They stabilize single-stranded cleavage complexes and, importantly, we have obtained the crystal structure where an NBTI binds gyrase-DNA in a single conformation lacking apparent static disorder. This directly proves the previously postulated NBTI mechanism of action and shows that they stabilize single-strand cleavage through asymmetric intercalation with a shift of the scissile phosphate. This crystal stucture shows that the chlorine forms a halogen bond with the backbone carbonyls of the two symmetry-related Ala68 residues. To the best of our knowledge, such a so-called symmetrical bifurcated halogen bond has not been identified in a biological system until now.

Language:English
Keywords:antibacterials, DNA gyrase inhibitors, drug discovery, Staphylococcus aureus, intercalators, novel bacterial topoisomerase inhibitors, NBTIs, symmetrical bifurcated halogen bonds, crystal structure, novel NBTIs mechanism of action, antimicrobials, DNA-binding proteins, drug development, X-ray crystallography
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:FFA - Faculty of Pharmacy
Publication status:Published
Publication version:Version of Record
Year:2021
Number of pages:13 str.
Numbering:Vol. 12, art. 150
PID:20.500.12556/RUL-144808 This link opens in a new window
UDC:577
ISSN on article:2041-1723
DOI:10.1038/s41467-020-20405-8 This link opens in a new window
COBISS.SI-ID:46272259 This link opens in a new window
Publication date in RUL:14.03.2023
Views:366
Downloads:28
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Nature communications
Shortened title:Nat. Commun.
Publisher:Nature Publishing Group
ISSN:2041-1723
COBISS.SI-ID:2315876 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Secondary language

Language:Slovenian
Keywords:biokemija, DNK, Escherichia coli, zaviralci

Projects

Funder:ARRS - Slovenian Research Agency
Project number:P1-0017
Name:Modeliranje kemijskih procesov in lastnosti spojin

Funder:ARRS - Slovenian Research Agency
Project number:P1-0208
Name:Farmacevtska kemija: načrtovanje, sinteza in vrednotenje učinkovin

Funder:UKRI - UK Research and Innovation
Funding programme:BBSRC, Institute Strategic Programme
Project number:BB/P012523/1

Funder:WT - Wellcome Trust
Funding programme:Investigator Award
Project number:110072/Z/15/Z

Funder:UKRI - UK Research and Innovation
Funding programme:BBSRC
Project number:BB/S507921/1
Name:John Innes Centre Flexible Talent Mobility Account

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back